← Coverage
TXG 10x Genomics
Biotech · NASDAQ · 한국어 페이지
Single-cell and spatial genomics instruments made in California; trade data only catches exports (mainly to China).
Current-quarter revenue estimate
Quarter ending Sep 2026 · reports Nov 5, 2026
Our estimate
$159M
$147M–$171M
vs a year ago
+6.7%
vs consensus
+7.6%
Low confidence · within ±5% in 5 of 11 backtested quarters, average error 5.9%. Model: company guidance adjusted by its historical beat rate.
Industry flow
California → China lab instrument exports · to Aug 2026
+0.3%last 3 months vs a year earlier
No company-specific flow — this is an industry-wide flow for context.
Mapped data flows
How each flow moves with quarterly revenue (year-over-year correlation, flow leading by 0–2 quarters).
| Flow | Stage | Revenue link | Correlation | Data to |
|---|---|---|---|---|
California → China lab instrument exports US Census Bureau | Production shipments | A Direct link | 0.71 | Aug 2026 |
California → China diagnostic reagent exports US Census Bureau | Production shipments | C Industry context | 0.47 · leads 1Q | Aug 2026 |
California diagnostic reagent exports US Census Bureau | End demand | D Weak link | 0.25 · leads 1Q | Aug 2026 |
A ≥0.7 direct link · B ≥0.5 linked · C ≥0.3 industry context · D weak. Fewer than 8 comparable quarters caps the grade at C.